The proposed sale is de minimis and likely part of routine portfolio management. Monitor for any subsequent Form 4 filings to confirm execution, but no material impact is expected.
KROS drugs
KROS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $10.30entry
- T+1 · 20h ago −2.62%α −0.71% · $10.03
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Anne Prener filed a Form 144 notice of intent to sell 574 shares of Keros Therapeutics common stock, with an approximate market value of $5,619 based on the filing date price. The shares were acquired through RSU vesting on August 15, 2026, and the sale is scheduled for November 12, 2026. The proposed sale is very small relative to the company's market cap and represents a routine diversification move by a director.
Key Facts
- Director Anne Prener filed Form 144 to sell 574 shares of Keros Therapeutics common stock.
- Estimated proceeds: $5,619 (based on filing date price of ~$9.79 per share).
- Shares were acquired via RSU vesting on August 15, 2026.
- Sale is scheduled for November 12, 2026.
- The filing is an advance notice of intent to sell, not a completed transaction.
Financial Impact
574 shares, approximately $5,619 in value, representing a negligible fraction of market cap.
Risk Factors
- Insider selling could be perceived negatively if followed by larger sales, but this filing alone is immaterial.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001173 |
| Document: 0001969223-26-001173-index.html | 0001969223-26-001173 |
| Document: 0001969223-26-001173.txt | 0001969223-26-001173 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers